Literature DB >> 22532688

Multiple antigenic sites are involved in blocking the interaction of GII.4 norovirus capsid with ABH histo-blood group antigens.

Gabriel I Parra1, Eugenio J Abente, Carlos Sandoval-Jaime, Stanislav V Sosnovtsev, Karin Bok, Kim Y Green.   

Abstract

Noroviruses are major etiological agents of acute viral gastroenteritis. In 2002, a GII.4 variant (Farmington Hills cluster) spread so rapidly in the human population that it predominated worldwide and displaced previous GII.4 strains. We developed and characterized a panel of six monoclonal antibodies (MAbs) directed against the capsid protein of a Farmington Hills-like GII.4 norovirus strain that was associated with a large hospital outbreak in Maryland in 2004. The six MAbs reacted with high titers against homologous virus-like particles (VLPs) by enzyme-linked immunoassay but did not react with denatured capsid protein in immunoblots. The expression and self-assembly of newly developed genogroup I/II chimeric VLPs showed that five MAbs bound to the GII.4 protruding (P) domain of the capsid protein, while one recognized the GII.4 shell (S) domain. Cross-competition assays and mutational analyses showed evidence for at least three distinct antigenic sites in the P domain and one in the S domain. MAbs that mapped to the P domain but not the S domain were able to block the interaction of VLPs with ABH histo-blood group antigens (HBGA), suggesting that multiple antigenic sites of the P domain are involved in HBGA blocking. Further analysis showed that two MAbs mapped to regions of the capsid that had been associated with the emergence of new GII.4 variants. Taken together, our data map antibody and HBGA carbohydrate binding to proximal regions of the norovirus capsid, showing that evolutionary pressures on the norovirus capsid protein may affect both antigenic and carbohydrate recognition phenotypes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22532688      PMCID: PMC3416322          DOI: 10.1128/JVI.06729-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  68 in total

1.  Epitopes in the P2 domain of norovirus VP1 recognized by monoclonal antibodies that block cell interactions.

Authors:  Vance P Lochridge; Kathryn L Jutila; Joel W Graff; Michele E Hardy
Journal:  J Gen Virol       Date:  2005-10       Impact factor: 3.891

2.  Norovirus classification and proposed strain nomenclature.

Authors:  Du-Ping Zheng; Tamie Ando; Rebecca L Fankhauser; R Suzanne Beard; Roger I Glass; Stephan S Monroe
Journal:  Virology       Date:  2005-12-15       Impact factor: 3.616

3.  Characterization of a cross-reactive linear epitope in human genogroup I and bovine genogroup III norovirus capsid proteins.

Authors:  Carrie A Batten; Ian N Clarke; Sarah L Kempster; Stefan L Oliver; Janice C Bridger; Paul R Lambden
Journal:  Virology       Date:  2006-08-24       Impact factor: 3.616

4.  Expression and self-assembly of recombinant capsid protein from the antigenically distinct Hawaii human calicivirus.

Authors:  K Y Green; A Z Kapikian; J Valdesuso; S Sosnovtsev; J J Treanor; J F Lew
Journal:  J Clin Microbiol       Date:  1997-07       Impact factor: 5.948

5.  Identification of Genogroup I and Genogroup II broadly reactive epitopes on the norovirus capsid.

Authors:  Tracy Dewese Parker; Noritoshi Kitamoto; Tomoyuki Tanaka; Anne M Hutson; Mary K Estes
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

6.  X-ray crystallographic structure of the Norwalk virus capsid.

Authors:  B V Prasad; M E Hardy; T Dokland; J Bella; M G Rossmann; M K Estes
Journal:  Science       Date:  1999-10-08       Impact factor: 47.728

7.  Multivalent norovirus vaccines induce strong mucosal and systemic blocking antibodies against multiple strains.

Authors:  Anna D LoBue; Lisa Lindesmith; Boyd Yount; Patrick R Harrington; Joseph M Thompson; Robert E Johnston; Christine L Moe; Ralph S Baric
Journal:  Vaccine       Date:  2006-04-18       Impact factor: 3.641

8.  Feline calicivirus capsid protein expression and capsid assembly in cultured feline cells.

Authors:  K Geissler; K Schneider; A Fleuchaus; C R Parrish; G Sutter; U Truyen
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

9.  Genotype 1 and genotype 2 bovine noroviruses are antigenically distinct but share a cross-reactive epitope with human noroviruses.

Authors:  S L Oliver; C A Batten; Y Deng; M Elschner; P Otto; A Charpilienne; I N Clarke; J C Bridger; P R Lambden
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

10.  Genetic and antigenic diversity among noroviruses.

Authors:  Grant S Hansman; Katsuro Natori; Haruko Shirato-Horikoshi; Satoko Ogawa; Tomoichiro Oka; Kazuhiko Katayama; Tomoyuki Tanaka; Tatsuya Miyoshi; Kenji Sakae; Shinichi Kobayashi; Michiyo Shinohara; Kazue Uchida; Nakao Sakurai; Kuniko Shinozaki; Mineyuki Okada; Yoshiyuki Seto; Kunio Kamata; Noriyo Nagata; Keiko Tanaka; Tatsuo Miyamura; Naokazu Takeda
Journal:  J Gen Virol       Date:  2006-04       Impact factor: 3.891

View more
  27 in total

Review 1.  Emergence of norovirus strains: A tale of two genes.

Authors:  Gabriel I Parra
Journal:  Virus Evol       Date:  2019-11-25

2.  Mapping broadly reactive norovirus genogroup I and II monoclonal antibodies.

Authors:  Sue E Crawford; Nadim Ajami; Tracy Dewese Parker; Noritoshi Kitamoto; Katsuro Natori; Naokazu Takeda; Tomoyuki Tanaka; Baijun Kou; Robert L Atmar; Mary K Estes
Journal:  Clin Vaccine Immunol       Date:  2014-11-26

3.  Structural basis for norovirus neutralization by an HBGA blocking human IgA antibody.

Authors:  Sreejesh Shanker; Rita Czakó; Gopal Sapparapu; Gabriela Alvarado; Maria Viskovska; Banumathi Sankaran; Robert L Atmar; James E Crowe; Mary K Estes; B V Venkataram Prasad
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-19       Impact factor: 11.205

4.  Identification and characterization of antibody-binding epitopes on the norovirus GII.3 capsid.

Authors:  Jackie E Mahar; Nicole C Donker; Karin Bok; Gert H Talbo; Kim Y Green; Carl D Kirkwood
Journal:  J Virol       Date:  2013-11-27       Impact factor: 5.103

5.  The diversity of the immune response to the A2 domain of human factor VIII.

Authors:  Rebecca C Markovitz; John F Healey; Ernest T Parker; Shannon L Meeks; Pete Lollar
Journal:  Blood       Date:  2013-01-24       Impact factor: 22.113

6.  Newly isolated mAbs broaden the neutralizing epitope in murine norovirus.

Authors:  Abimbola O Kolawole; Chunsheng Xia; Ming Li; Monica Gamez; Chenchen Yu; Christine M Rippinger; Ryan E Yucha; Thomas J Smith; Christiane E Wobus
Journal:  J Gen Virol       Date:  2014-06-04       Impact factor: 3.891

Review 7.  Anti-norovirus therapeutics: a patent review (2010-2015).

Authors:  Anushka C Galasiti Kankanamalage; Pathum M Weerawarna; Yunjeong Kim; Kyeong-Ok Chang; William C Groutas
Journal:  Expert Opin Ther Pat       Date:  2016       Impact factor: 6.674

8.  The feline calicivirus leader of the capsid protein is associated with cytopathic effect.

Authors:  Eugenio J Abente; Stanislav V Sosnovtsev; Carlos Sandoval-Jaime; Gabriel I Parra; Karin Bok; Kim Y Green
Journal:  J Virol       Date:  2012-12-26       Impact factor: 5.103

9.  A Luciferase Immunoprecipitation System (LIPS) assay for profiling human norovirus antibodies.

Authors:  Christine M Tin; Lijuan Yuan; Rachel J Dexter; Gabriel I Parra; Tammy Bui; Kim Y Green; Stanislav V Sosnovtsev
Journal:  J Virol Methods       Date:  2017-07-01       Impact factor: 2.014

10.  Development of Norwalk virus-specific monoclonal antibodies with therapeutic potential for the treatment of Norwalk virus gastroenteritis.

Authors:  Zhaochun Chen; Stanislav V Sosnovtsev; Karin Bok; Gabriel I Parra; Michelle Makiya; Liane Agulto; Kim Y Green; Robert H Purcell
Journal:  J Virol       Date:  2013-06-19       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.